Cargando…

Non-small cell lung cancer harboring EGFR G724S mutation and exon 19 deletion responded to afatinib monotherapy after multiple lines of target therapies

Epidermal growth factor receptor (EGFR) G724S mutation represents a resistance mechanism to first- and third-generation EGFR tyrosine kinase inhibitors. Limited data are available regarding the efficacy of afatinib in patients with non-small cell lung cancer (NSCLC) harboring G724S mutation, particu...

Descripción completa

Detalles Bibliográficos
Autores principales: Cortiula, Francesco, Pelizzari, Giacomo, Corvaja, Carla, De Maglio, Giovanna, Fasola, Gianpiero
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9481291/
https://www.ncbi.nlm.nih.gov/pubmed/35979997
http://dx.doi.org/10.1097/CAD.0000000000001321
_version_ 1784791231339954176
author Cortiula, Francesco
Pelizzari, Giacomo
Corvaja, Carla
De Maglio, Giovanna
Fasola, Gianpiero
author_facet Cortiula, Francesco
Pelizzari, Giacomo
Corvaja, Carla
De Maglio, Giovanna
Fasola, Gianpiero
author_sort Cortiula, Francesco
collection PubMed
description Epidermal growth factor receptor (EGFR) G724S mutation represents a resistance mechanism to first- and third-generation EGFR tyrosine kinase inhibitors. Limited data are available regarding the efficacy of afatinib in patients with non-small cell lung cancer (NSCLC) harboring G724S mutation, particularly after osimertinib. A patient diagnosed with advanced EGFR-mutated (exon 19 deletion) NSCLC after several lines of treatment – gefitinib, osimertinib, heat shock protein inhibitors and chemotherapy-developed EGFR G724S mutation retaining the exon 19 deletion. She was then treated successfully with afatinib leading to a progression free survival of 9 months (and counting). This is the first report of the emergence of G724S mutation, together with ex19del, after three subsequent lines of therapy following progressive disease to Osimertinib, and we report for the first time the activity of afatinib against EGFR exon 18 G724S mutation in this setting.
format Online
Article
Text
id pubmed-9481291
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-94812912022-09-21 Non-small cell lung cancer harboring EGFR G724S mutation and exon 19 deletion responded to afatinib monotherapy after multiple lines of target therapies Cortiula, Francesco Pelizzari, Giacomo Corvaja, Carla De Maglio, Giovanna Fasola, Gianpiero Anticancer Drugs Case Reports Epidermal growth factor receptor (EGFR) G724S mutation represents a resistance mechanism to first- and third-generation EGFR tyrosine kinase inhibitors. Limited data are available regarding the efficacy of afatinib in patients with non-small cell lung cancer (NSCLC) harboring G724S mutation, particularly after osimertinib. A patient diagnosed with advanced EGFR-mutated (exon 19 deletion) NSCLC after several lines of treatment – gefitinib, osimertinib, heat shock protein inhibitors and chemotherapy-developed EGFR G724S mutation retaining the exon 19 deletion. She was then treated successfully with afatinib leading to a progression free survival of 9 months (and counting). This is the first report of the emergence of G724S mutation, together with ex19del, after three subsequent lines of therapy following progressive disease to Osimertinib, and we report for the first time the activity of afatinib against EGFR exon 18 G724S mutation in this setting. Lippincott Williams & Wilkins 2022-08-12 2022-10 /pmc/articles/PMC9481291/ /pubmed/35979997 http://dx.doi.org/10.1097/CAD.0000000000001321 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Case Reports
Cortiula, Francesco
Pelizzari, Giacomo
Corvaja, Carla
De Maglio, Giovanna
Fasola, Gianpiero
Non-small cell lung cancer harboring EGFR G724S mutation and exon 19 deletion responded to afatinib monotherapy after multiple lines of target therapies
title Non-small cell lung cancer harboring EGFR G724S mutation and exon 19 deletion responded to afatinib monotherapy after multiple lines of target therapies
title_full Non-small cell lung cancer harboring EGFR G724S mutation and exon 19 deletion responded to afatinib monotherapy after multiple lines of target therapies
title_fullStr Non-small cell lung cancer harboring EGFR G724S mutation and exon 19 deletion responded to afatinib monotherapy after multiple lines of target therapies
title_full_unstemmed Non-small cell lung cancer harboring EGFR G724S mutation and exon 19 deletion responded to afatinib monotherapy after multiple lines of target therapies
title_short Non-small cell lung cancer harboring EGFR G724S mutation and exon 19 deletion responded to afatinib monotherapy after multiple lines of target therapies
title_sort non-small cell lung cancer harboring egfr g724s mutation and exon 19 deletion responded to afatinib monotherapy after multiple lines of target therapies
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9481291/
https://www.ncbi.nlm.nih.gov/pubmed/35979997
http://dx.doi.org/10.1097/CAD.0000000000001321
work_keys_str_mv AT cortiulafrancesco nonsmallcelllungcancerharboringegfrg724smutationandexon19deletionrespondedtoafatinibmonotherapyaftermultiplelinesoftargettherapies
AT pelizzarigiacomo nonsmallcelllungcancerharboringegfrg724smutationandexon19deletionrespondedtoafatinibmonotherapyaftermultiplelinesoftargettherapies
AT corvajacarla nonsmallcelllungcancerharboringegfrg724smutationandexon19deletionrespondedtoafatinibmonotherapyaftermultiplelinesoftargettherapies
AT demagliogiovanna nonsmallcelllungcancerharboringegfrg724smutationandexon19deletionrespondedtoafatinibmonotherapyaftermultiplelinesoftargettherapies
AT fasolagianpiero nonsmallcelllungcancerharboringegfrg724smutationandexon19deletionrespondedtoafatinibmonotherapyaftermultiplelinesoftargettherapies